Prostate cancer (PCa) is one of the most prevalent malignancies in men worldwide[1] Given the critical role of the androgen receptor (AR) signaling pathway in tumorigenesis, surgical or medical androgen deprivation therapy (ADT) is the primary treatment for prostate cancer.[2] However, patients eventually progress to castration‐resistant prostate cancer (CRPC), which contributes to the majority of prostate cancer‐related deaths. The gene discussed is AR; the disease is prostate carcinoma.